Evidence map›Paper›PMID 37554056›Full record

ReviewJournal of neurochemistry2024

The multifaceted roles of the brain glycogen.

Kia H Markussen, Manuela Corti, Barry J Byrne, Craig W Vander Kooi, Ramon C Sun, Matthew S Gentry

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of neurochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Kia H MarkussenDepartment of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.ORCID 0000-0001-9446-0400
Manuela CortiDepartment of Pediatrics, Powell Gene Therapy Center, College of Medicine, University of Florida, Gainesville, Florida, USA.ORCID 0000-0002-6391-4139
Barry J ByrneDepartment of Pediatrics, Powell Gene Therapy Center, College of Medicine, University of Florida, Gainesville, Florida, USA.ORCID 0000-0002-7302-1756
Craig W Vander KooiDepartment of Biochemistry & Molecular Biology, College of Medicine, University of Florida, Gainesville, Florida, USA.ORCID 0000-0002-7463-3914
Ramon C SunDepartment of Biochemistry & Molecular Biology, College of Medicine, University of Florida, Gainesville, Florida, USA.ORCID 0000-0002-3009-1850
Matthew S GentryDepartment of Biochemistry & Molecular Biology, College of Medicine, University of Florida, Gainesville, Florida, USA.ORCID 0000-0001-5253-9049
University of Florida · USUniversity of Kentucky · US

Funding

Suppressing glycogen storage with small molecule inhibitors as a therapeutic approach to Lafora DiseaseP01NS097197 · NINDS · UNIVERSITY OF KENTUCKY · PI GAO, TIANYAN · 2016 to 2021
$9.0M
Brain Glycogen-Metabolism,Mechanisms, and Therapeutic PotentialR35NS116824 · NINDS · UNIVERSITY OF KENTUCKY · PI Matthew S. Gentry · 2020 to 2026
$8.2M
Immunomodulation Approaches to Improve Safety And Efficacy of Gene Therapy Treatment in Friedreich’s AtaxiaU01NS116752 · NINDS · UNIVERSITY OF FLORIDA · PI CORTI, MANUELA · 2021 to 2025
$3.8M
Deciphering the Glycan Code in Human Alzheimer’s Disease BrainR01AG078702 · NIA · UNIVERSITY OF KENTUCKY · PI Peggi M Angel, Sean Curtis Bendall · 2022 to 2026
$3.8M
Aberrant Glycogen in Lung Adenocarcinoma TumorigenesisR01CA266004 · NCI · UNIVERSITY OF KENTUCKY · PI Matthew S. Gentry, Ramon C. Sun · 2022 to 2026
$2.6M
Aberrant Glycogen Modulates Cerebral Glucose Metabolism in Aging and Alzheimer's DiseaseR01AG066653 · NIA · UNIVERSITY OF KENTUCKY · PI SUN, RAMON C. · 2020 to 2024
$1.9M
Ampakines and Respiratory NeuroplasticityR01HL139708 · NHLBI · UNIVERSITY OF FLORIDA · PI FULLER, DAVID D · 2018 to 2021
$1.5M
Treatment of Lafora disease with an antibody-enzyme fusionR33NS111081 · NINDS · UNIVERSITY OF FLORIDA · PI GENTRY, MATTHEW S. · 2023 to 2024
$751k
Adult Polyglucosan Body Disease Research FoundationChan Zuckerberg Initiative Rare As One GrantChelsea's Hope Lafora Children Research FoundationGlut1 Deficiency FoundationNCI NIH HHS R01 CA266004NHLBI NIH HHS HL139708-02NHLBI NIH HHS R01 HL139708NIA NIH HHS R01 AG066653NIA NIH HHS R01 AG078702NIA NIH HHS U01-NS116752-01A1NINDS NIH HHS P01 NS097197NINDS NIH HHS R33 NS111081NINDS NIH HHS R35 NS116824NINDS NIH HHS U01 NS116752Rally Foundation IndependentSt. Baldrick's FoundationV Foundation
6 · The paper itself

Abstract

Glycogen is a biologically essential macromolecule that is directly involved in multiple human diseases. While its primary role in carbohydrate storage and energy metabolism in the liver and muscle is well characterized, recent research has highlighted critical metabolic and non-metabolic roles for glycogen in the brain. In this review, the emerging roles of glycogen homeostasis in the healthy and diseased brain are discussed with a focus on advancing our understanding of the role of glycogen in the brain. Innovative technologies that have led to novel insights into glycogen functions are detailed. Key insights into how cellular localization impacts neuronal and glial function are discussed. Perturbed glycogen functions are observed in multiple disorders of the brain, including where it serves as a disease driver in the emerging category of neurological glycogen storage diseases (n-GSDs). n-GSDs include Lafora disease (LD), adult polyglucosan body disease (APBD), Cori disease, Glucose transporter type 1 deficiency syndrome (G1D), GSD0b, and late-onset Pompe disease (PD). They are neurogenetic disorders characterized by aberrant glycogen which results in devastating neurological and systemic symptoms. In the most severe cases, rapid neurodegeneration coupled with dementia results in death soon after diagnosis. Finally, we discuss current treatment strategies that are currently being developed and have the potential to be of great benefit to patients with n-GSD. Taken together, novel technologies and biological insights have resulted in a renaissance in brain glycogen that dramatically advanced our understanding of both biology and disease. Future studies are needed to expand our understanding and the multifaceted roles of glycogen and effectively apply these insights to human disease.

Indexed as

BrainGlycogenAnimalsGlycogen Storage DiseaseHumansGlycogenbrain metabolismcongenital disorders of glycosylationepilepsyglycogenglycogen storage diseaseN‐linked glycosylation

Identifiers

PMID37554056
PMCPMC10901277
OpenAlexW4385684538

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.